Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Aligos Therapeutics
- Puhelinnumero: 800-466-6059
- Sähköposti: info@aligos.com
Opiskelupaikat
-
-
Wisconsin
-
Madison, Wisconsin, Yhdysvallat, 53704
- Aligos Investigational Site
-
Ottaa yhteyttä:
- Aligos Investigational Site
- Puhelinnumero: 800-466-6059
- Sähköposti: info@aligos.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria: Key Inclusion Criteria
- Parts A and B only: Male or female between 18 and 60 years of age
- Part C only: Males between 18 and 55 years of age.
- Body mass index between 18.0 kg/m2 and 32.0 kg/m2
- In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
- Part C only: History of a minimum of 1 bowel movement per day.
Exclusion Criteria: Key Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
-
History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
-
History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
-
Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.
-
Positive hepatitis panel and/or positive human immunodeficiency virus test.
-
Parts A and B only: Any of the following at screening or check-in:
- QTcF >450 ms in males or >470 ms in females
- QRS duration >120 ms
- PR interval >210 ms
- findings which would make QTc measurements difficult or QTc data uninterpretable
-
Administration of any vaccine within 30 days prior to dosing.
-
Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing
-
Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.
-
Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: ALG-000184
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of ALG-000184 |
|
Placebo Comparator: Placebo
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of Placebo |
|
Muut: [14C]ALG-000184
|
Single oral dose of [14C]ALG-000184 Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184 |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Safety and Tolerability (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-τ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including tmax t1/2 |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including ARAUC |
From enrollment to end of treatment at 10 days
|
|
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Metabolic profiles of ALG-000184 (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Identification of ALG-000184 (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Bioavailability of ALG-001075 (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075 |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2 |
From enrollment to end of treatment at 10 days
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
QTc (Part A and B)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants |
From enrollment to end of treatment at 10 days
|
|
Safety and Tolerability (Part C)
Aikaikkuna: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- ALG-000184-209
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .